Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accounts Payables: 2022-2025

Historic Accounts Payables for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $1.4 million.

  • InMed Pharmaceuticals' Accounts Payables rose 11.72% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 11.72%. This contributed to the annual value of $1.4 million for FY2025, which is 15.10% down from last year.
  • InMed Pharmaceuticals' Accounts Payables amounted to $1.4 million in FY2025, which was down 15.10% from $1.7 million recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Accounts Payables high stood at $2.4 million for FY2022, and its period low was $1.4 million during FY2025.
  • Its 3-year average for Accounts Payables is $1.6 million, with a median of $1.6 million in 2023.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Accounts Payables tumbled by 33.39% in 2023, and later rose by 2.81% in 2024.
  • MRY analysis of 4 years shows InMed Pharmaceuticals' Accounts Payables stood at $2.4 million in 2022, then plummeted by 33.39% to $1.6 million in 2023, then increased by 2.81% to $1.7 million in 2024, then fell by 15.10% to $1.4 million in 2025.
  • Its Accounts Payables was $1.4 million in FY2025, compared to $1.7 million in FY2024 and $1.6 million in FY2023.